Cassava craters despite denying Alzheimer's data allegations
A Texan biotech company focused on Alzheimer’s disease saw its share price crash by 24% during Wednesday morning’s trading after claims were posted about the firm’s scientific integrity online on Tuesday after market hours.
A citizen petition signed by a lawyer on behalf of unnamed clients called for the company’s studies of the experimental Alzheimer’s drug simufilam to be halted, alleging that some results on the candidate appeared to suggest data manipulation.
"As a science company, we champion facts that can be evaluated and verified"In February, Cassava said that treatment with simufilam had resulted in improved reasoning and behavior in a trial involving less than 100 people and without a control arm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze